Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lung Neoplasms 3Esophageal Neoplasms 3Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Meningeal Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 52Paclitaxel 19Cisplatin 14Carboplatin 14lenvatinib 10Docetaxel 8Saline Solution 7Capecitabine 7Pemetrexed 6Oxaliplatin 6Gemcitabine 6Fluorouracil 6Leucovorin 5Albumin-Bound Paclitaxel 5olaparib 4belzutifan 4Bevacizumab 4130-nm albumin-bound paclitaxel 4patritumab deruxtecan 3Glucose 3Acetaminophen 3liposomal doxorubicin 2Levoleucovorin 2Irinotecan 2Histamine H2 Antagonists 2Histamine Antagonists 2Etoposide 2Doxorubicin 2Dexamethasone 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × patritumab deruxtecan × 90 days × Clear all
NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT04165070 2026-05-18

MK-3475-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
450 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06445972 2026-05-12

MK-3475-06D

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
210 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡